• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC

New Search Back to Search Results
Note: this medical device record is a supplement. The device description may have changed. Be sure to look at the original PMA to get an up-to-date view of this device.
Classification Nameimmunohistochemistry assay, antibody, epidermal growth factor receptor
Generic Nameimmunohistochemistry assay, antibody, epidermal growth factor receptor
Regulation Number864.1860
PMA NumberP030044
Supplement NumberS002
Date Received04/03/2006
Decision Date09/27/2006
Product Code
NQF[ Registered Establishments with NQF ]
Advisory Committee Pathology
Supplement Typenormal 180 day track
Supplement Reason change design/components/specifications/material
Expedited Review Granted? No
Combination Product No
Approval Order Statement 
Approval for adding a new therapy vectibix (panitumumab) to intended use. The device, as modified, will be marketed under the trade name dako egfr pharmdx kit and is indicated for: the egfr pharmdx assay is a qualitative immunohistochemical (ihc) kit system to identify epidermal growth factor receptor (egfr) expression in normal and neoplatic tissues routinely-fixed for histological evaluatin. Egfr pharmdx specifically detects the egfr (her1) protein in egfr-expressing cells. Egfr pharmdx is indicated as an aid in identifying colorectal cancer patients eligible for treatment with erbitux (cetuximab), or vectibix (panitumumab).